C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on June 10, 2024, reporting events that occurred on June 6 and June 7, 2024. The filing addresses significant changes to the Company's Board of Directors, including the resignation of a director, the election of a new director, and a change in the Board Chair.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation of Director: Glenn Dubin resigned from the Board of Directors, effective upon the appointment of his successor on June 7, 2024. The Company stated there are no disagreements regarding operations, policies, or practices.
- Election of Director: Ron Cooper was appointed as a director on June 7, 2024. He is designated as a Class II director serving until the 2025 Annual Meeting of Stockholders.
- Change in Board Chair: Bruce Downey resigned as Chair of the Board but will remain a member of the Board and the Nominating and Corporate Governance (NCG) Committee. Ron Cooper was appointed as the new Chair of the Board.
- Compensation: Mr. Cooper was granted stock options to purchase up to 65,000 shares of common stock. The award vests one-third on the first anniversary of the grant date, with the remainder vesting quarterly over the subsequent two years, contingent on continued service.
Outlook, Risks, and Management Commentary
The Board determined that Mr. Cooper is independent under Nasdaq listing standards and meets the requirements for independence of compensation committee members. An indemnification agreement was entered into with Mr. Cooper in the same form as used with other directors. The Company issued a press release on June 10, 2024, announcing these appointments, which is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Confirm the effective date of Glenn Dubin's resignation and the start of Ron Cooper's tenure as Chair.
- Review the vesting schedule and terms of the 65,000 stock options granted to Ron Cooper.
- Verify the composition of the Board and the NCG Committee following these changes.
- Check for any subsequent filings regarding the transition of leadership responsibilities.